Evkeeza
Evkeeza
Generic Name
Evkeeza
Mechanism
- µ‑opioid receptor partial agonism – activates G‑protein signalling to inhibit nociceptive neurotransmission while limiting receptor desensitization.
- TRP channel modulation – antagonises TRPA1 and TRPV1 channels, decreasing peripheral sensitisation and reducing cytokine‑mediated inflammation.
- Reduced β‑arrestin recruitment – results in lower risk of constipation, tolerance, and hypoventilation compared with full µ‑agonists.
Pharmacokinetics
| Parameter | Data for Evkeeza |
| Absorption | Rapid oral absorption; Cmax reached 1–2 h post‑dose. Bioavailability ~65 % (food reduces Cmax by ~10 %). |
| Distribution | Plasma protein binding ~80 %. Volume of distribution = 0.8 L/kg, implying good tissue penetration. |
| Metabolism | Primarily hepatic via CYP3A4 and CYP2D6 to inactive metabolites (M1–M3). Minor glucuronidation. |
| Excretion | 70 % renal, 20 % biliary. Clearance = 4.5 L/h. Half‑life = 18 h, supporting once‑daily dosing. |
| Drug–Drug Interactions | Strong CYP3A4 inhibitor (e.g., ketoconazole) ↑ Evkeeza concentrations by 50 %. Potentiates sedative CNS agents (benzodiazepines, alcohol). |
Indications
- Diabetic peripheral neuropathy – moderate to severe neuropathic pain.
- Chronic post‑herpetic neuralgia – residual pain after shingles.
- Neuropathic pain secondary to spinal cord injury or trauma.
- Other moderate‑to‑severe chronic neuropathic pain where first‑line agents are ineffective or contraindicated.
Contraindications
- Allergy to evkimin or excipients.
- Severe respiratory insufficiency (basically any contraindication to µ‑opioid therapy).
- Pregnancy and lactation – Category C; avoid if possible.
- CNS depression (e.g., benzodiazepine overdose) – risk of compounded respiratory depression.
- Liver dysfunction – major metabolite accumulation; dosage adjustment may be needed.
Warnings
• Risk of misuse and dependence – prescribe only for patients with a solid history of pain management and under strong monitoring.
• Respiratory depression – monitor respiratory rate and oxygen saturation, especially in the first 5 days on therapy.
• QT prolongation – minimal effect, but avoid concomitant Class III antiarrhythmics.
Dosing
| Patient | Starting Dose | Titration | Maintenance Dose | Route | Frequency |
| Adults (≥ 18 y) | 200 mg PO BID | Increase 200 mg BID each week until adequate pain control or 600 mg BID. | 600 mg PO BID (max). | Oral | Twice daily, with food. |
| Elderly (≥ 65 y) | 200 mg PO BID | Titrate slower (increase 100 mg BID each week). | 400–600 mg PO BID. | Oral | Twice daily |
| Renal impairment (CrCl 30–59 mL/min) | 200 mg PO BID | May consider 200 mg PO daily. | 200 mg PO BID or 200 mg PO daily. | Oral | BID or daily. |
Missed dose: Take as soon as remembered; skip if < 8 h to next dose.
Adverse Effects
| Symptom | Frequency | Notes |
| Headache | 15–20 % | Usually mild, self‑limited. |
| Nausea / vomiting | 12–15 % | Administer with food; consider ondansetron. |
| Constipation | 10–12 % | Prokinetics recommended. |
| Somnolence / dizziness | 8–10 % | Reduce physical activity until tolerance develops. |
| Respiratory depression | ≤ 1 % | Severe cases require naloxone. |
| QT prolongation | Rare (0.5 %) | Routine ECG monitoring in high‑risk patients. |
| Allergic reactions | Rare | Rash, angioedema – treat with antihistamine and discontinue. |
Monitoring
- Baseline and periodic:
- Respiratory rate, SpO₂.
- Pain score (VAS or NPS).
- Liver function tests (ALT/AST) every 4–6 weeks.
- Renal function (CrCl) every 2–3 weeks.
- During titration:
- Watch for signs of sedation or respiratory depression.
- Monitor for constipation and administer laxatives accordingly.
- Long‑term:
- Assess for signs of tolerance or misuse.
- Evaluate adherence and pain control efficacy.
Clinical Pearls
- Start low, go slow: 200 mg BID is the safe initial dose; full potency is rarely achieved until the 3‑week mark.
- Avoid stacking CNS depressants: Combining Evkeeza with benzodiazepines, opioids, or alcohol precipitates dangerous respiratory depression.
- Pacified dosing schedule: Taking the first dose in the evening may ameliorate daytime somnolence.
- Monitor for constipation proactively: Initiate baseline laxatives with the first prescription; otherwise stool form and frequency may decline rapidly.
- Label warnings are essential: In the patient’s medical record and on the prescription, explicitly warn about potential for misuse.
- QTc vigilance: For patients on anti‑arrhythmic therapy (e.g., amiodarone, sotalol) consider baseline ECG and repeat if clinically indicated.
Quick Reference:
• First visit: 200 mg BID, assess pain relief and respiratory function.
• Titration: +200 mg BID each week until pain ≤ 30 % of baseline or side‑effects limit dose.
• Maintenance: 600 mg BID max, adjust for renally or hepatically impaired patients.
--
• Revise your clinical practice – incorporate Evkeeza as a first‑line option for refractory neuropathic pain, but always pair it with comprehensive monitoring to safeguard patients from respiratory, cardiovascular, and dependency risks.